Illumina, Inc.
Illumina Appoints New Chief Medical Officer and Announces Departure of Chief Commercial Officer
Summary
Illumina, Inc. announced on January 8, 2026, the appointment of Dr. Eric Green as Chief Medical Officer, effective February 2, 2026. Dr. Green, a veteran genomics leader, will focus on advancing global medical strategy and increasing access to precision medicine solutions. Simultaneously, the company announced the departure of Chief Commercial Officer Everett Cunningham, who will be taking on the role of CEO at a life science tools company. Cunningham's departure is effective January 16, 2026, with Jacob Thaysen acting as interim Chief Commercial Officer until a successor is named.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement